"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B2,US 10670617 B2,053-008-720-109-741,2020-06-02,2020,US 201615580984 A,2016-06-08,US 201615580984 A;;US 201562172636 P;;US 201562194223 P;;US 2016/0036397 W,2015-06-08,Methods of assessing future memory loss by measuring polyunsaturated fatty acids,The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise determining the influx of polyunsaturated fatty acids (PUFAs) into the brain from plasma in a test subject and comparing this measured influx to a normal standard influx. An increase in influx of PUFAs from the plasma into the brain is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.,UNIV GEORGETOWN,FIANDACA MASSIMO S;;FEDEROFF HOWARD J,GEORGETOWN UNIVERSITY (2017-12-15),https://lens.org/053-008-720-109-741,Granted Patent,yes,3,0,4,9,0,A61K31/20;;A61K31/20;;A61K31/201;;A61K31/201;;A61K31/202;;A61K31/202;;G01N33/92;;G01N33/92;;G01N33/48;;G01N33/48;;G01N33/52;;G01N33/52;;G01N2800/2814;;G01N2800/2814;;G01N2800/2871;;G01N2800/2871;;G01N2800/50;;G01N2800/50;;G01N2800/52,G01N33/92;;A61K31/00;;A61K31/20;;A61K31/201;;A61K31/202;;A61K38/00;;G01N33/48;;G01N33/52,,3,2,080-961-522-392-14X;;030-006-556-108-515,10.1038/nrn3820;;25387473;;17901539;;10.1007/s12031-007-0060-1,"International Search Report issued in corresponding International Patent Application No. PCT/US2016/036397 dated Sep. 16, 2016.;;Bazinet et al., Polyunsaturated fatty acids and their metabolites in brain function and disease, Nature ReviewsNeuroscience, 2014, 15:771-785.;;Hamilton et al., Brain uptake and utilization of fatty acids, lipids and lipoproteins: application to neurological disorders, J. Mol. Neurosci., 2007, 33:2-11.",ACTIVE
2,WO,A1,WO 2016/200903 A1,031-840-794-202-727,2016-12-15,2016,US 2016/0036397 W,2016-06-08,US 201562172636 P;;US 201562194223 P,2015-06-08,METHODS OF ASSESSING FUTURE MEMORY LOSS BY MEASURING POLYUNSATURATED FATTY ACIDS,The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise determining the influx of polyunsaturated fatty acids (PU FAs) into the brain from plasma in a test subject and comparing this measured influx to a normal standard influx. An increase in influx of PUFAs from the plasma into the brain is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.,UNIV GEORGETOWN,FIANDACA MASSIMO S;;FEDEROFF HOWARD J,,https://lens.org/031-840-794-202-727,Patent Application,yes,3,0,4,9,0,A61K31/20;;A61K31/20;;A61K31/201;;A61K31/201;;A61K31/202;;A61K31/202;;G01N33/92;;G01N33/92;;G01N33/48;;G01N33/48;;G01N33/52;;G01N33/52;;G01N2800/2814;;G01N2800/2814;;G01N2800/2871;;G01N2800/2871;;G01N2800/50;;G01N2800/50;;G01N2800/52,A61K31/20;;A61K31/202;;G01N33/48;;G01N33/52,,2,2,030-006-556-108-515;;080-961-522-392-14X,17901539;;10.1007/s12031-007-0060-1;;10.1038/nrn3820;;25387473,"HAMILTON, JA ET AL.: ""Brain Uptake and Utilization of Fatty Acids, Lipids and Lipoproteins: Application to Neurological Disorders."", JOURNAL OF MOLECULAR NEUROSCIENCE., vol. 33, no. 1, 2007, pages 2 - 11, XP055334682;;BAZINET, RP ET AL.: ""Polyunsaturated Fatty Acids and Their Metabolites in Brain Function and Disease."", NATURE REVIEWS NEUROSCIENCE., vol. 15, no. 12, 2014, pages 772 - 785, XP055334685",PENDING
3,US,A1,US 2018/0196073 A1,160-559-520-571-608,2018-07-12,2018,US 201615580984 A,2016-06-08,US 201615580984 A;;US 201562172636 P;;US 201562194223 P;;US 2016/0036397 W,2015-06-08,Methods of Assessing Future Memory Loss by Measuring Polyunsaturated Fatty Acids,The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise determining the influx of polyunsaturated fatty acids (PU FAs) into the brain from plasma in a test subject and comparing this measured influx to a normal standard influx. An increase in influx of PUFAs from the plasma into the brain is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.,UNIV GEORGETOWN,FIANDACA MASSIMO S;;FEDEROFF HOWARD J,GEORGETOWN UNIVERSITY (2017-12-15),https://lens.org/160-559-520-571-608,Patent Application,yes,0,1,4,9,0,A61K31/20;;A61K31/20;;A61K31/201;;A61K31/201;;A61K31/202;;A61K31/202;;G01N33/92;;G01N33/92;;G01N33/48;;G01N33/48;;G01N33/52;;G01N33/52;;G01N2800/2814;;G01N2800/2814;;G01N2800/2871;;G01N2800/2871;;G01N2800/50;;G01N2800/50;;G01N2800/52,G01N33/92;;A61K31/202;;G01N33/52,,0,0,,,,ACTIVE
4,US,A1,US 2020/0363436 A1,117-090-788-267-522,2020-11-19,2020,US 202016889771 A,2020-06-01,US 202016889771 A;;US 201715580984 A;;US 2016/0036397 W;;US 201562172636 P;;US 201562194223 P,2015-06-08,METHODS OF ASSESSING FUTURE MEMORY LOSS BY MEASURING POLYUNSATURATED FATTY ACIDS,The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise determining the influx of polyunsaturated fatty acids (PUFAs) into the brain from plasma in a test subject and comparing this measured influx to a normal standard influx. An increase in influx of PUFAs from the plasma into the brain is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.,UNIV GEORGETOWN,FIANDACA MASSIMO S;;FEDEROFF HOWARD J,,https://lens.org/117-090-788-267-522,Patent Application,yes,0,1,4,9,0,A61K31/20;;A61K31/20;;A61K31/201;;A61K31/201;;A61K31/202;;A61K31/202;;G01N33/92;;G01N33/92;;G01N33/48;;G01N33/48;;G01N33/52;;G01N33/52;;G01N2800/2814;;G01N2800/2814;;G01N2800/2871;;G01N2800/2871;;G01N2800/50;;G01N2800/50;;G01N2800/52,G01N33/92;;A61K31/20;;A61K31/201;;A61K31/202;;G01N33/48;;G01N33/52,,0,0,,,,DISCONTINUED
5,EP,A1,EP 3146346 A1,119-145-616-303-388,2017-03-29,2017,EP 15796208 A,2015-05-26,US 201462002453 P;;US 2015/0032490 W,2014-05-23,EXOSOME AND LIPID BIOMARKERS FOR MEMORY LOSS,,UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;FEDEROFF HOWARD J,,https://lens.org/119-145-616-303-388,Patent Application,yes,0,0,4,4,0,G01N33/92;;G01N2800/2814;;G01N2800/50;;G01N2800/52;;G01N33/6896;;G01N33/92;;G01N2800/2814;;G01N2800/50;;G01N2800/52;;G01N33/6896,G01N33/68,,0,0,,,,DISCONTINUED
6,US,A1,US 2017/0184613 A1,124-015-528-141-839,2017-06-29,2017,US 201515312804 A,2015-05-26,US 201515312804 A;;US 201462002453 P;;US 2015/0032490 W,2014-05-23,EXOSOME AND LIPID BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one sample from the subject to determine a value of the subject's exosomal profile or combined biomarker profile (lipids plus exosomal cargo) and comparing the value of the subject's exosomal or combined biomarker profile with the value of a normal exosomal or biomarker profile, respectively. A change in the value of the subject's exosomal or combined biomarker profile, including a change in the subject's exosomal or combined biomarker profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;FEDEROFF HOWARD J,GEORGETOWN UNIVERSITY (2015-06-18);;UNIVERSITY OF ROCHESTER (2015-07-01),https://lens.org/124-015-528-141-839,Patent Application,yes,0,0,4,4,0,G01N33/92;;G01N2800/2814;;G01N2800/50;;G01N2800/52;;G01N33/6896;;G01N33/92;;G01N2800/2814;;G01N2800/50;;G01N2800/52;;G01N33/6896,G01N33/68;;G01N33/92,,0,0,,,,DISCONTINUED
7,EP,A4,EP 3146346 A4,034-179-857-938-679,2018-03-21,2018,EP 15796208 A,2015-05-26,US 201462002453 P;;US 2015/0032490 W,2014-05-23,EXOSOME AND LIPID BIOMARKERS FOR MEMORY LOSS,,UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;FEDEROFF HOWARD J,,https://lens.org/034-179-857-938-679,Search Report,no,2,0,4,4,0,G01N33/92;;G01N2800/2814;;G01N2800/50;;G01N2800/52;;G01N33/6896;;G01N33/92;;G01N2800/2814;;G01N2800/50;;G01N2800/52;;G01N33/6896,G01N33/92;;G01N33/68,,2,1,086-828-190-830-099,pmc3281682;;10.1074/jbc.m111.277061;;22057275,"SUDAD SAMAN ET AL: ""Exosome-associated Tau Is Secreted in Tauopathy Models and Is Selectively Phosphorylated in Cerebrospinal Fluid in Early Alzheimer Disease"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 6, 3 February 2012 (2012-02-03), pages 3842 - 3849, XP055424914, ISSN: 0021-9258, DOI: 10.1074/jbc.M111.277061;;See also references of WO 2015179875A1",DISCONTINUED
8,WO,A1,WO 2015/179875 A1,060-647-407-400-203,2015-11-26,2015,US 2015/0032490 W,2015-05-26,US 201462002453 P,2014-05-23,EXOSOME AND LIPID BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one sample from the subject to determine a value of the subject's exosomal profile or combined biomarker profile (lipids plus exosomal cargo) and comparing the value of the subject's exosomal or combined biomarker profile with the value of a normal exosomal or biomarker profile, respectively. A change in the value of the subject's exosomal or combined biomarker profile, including a change in the subject's exosomal or combined biomarker profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;FEDEROFF HOWARD J,,https://lens.org/060-647-407-400-203,Patent Application,yes,5,3,4,4,0,G01N33/92;;G01N2800/2814;;G01N2800/50;;G01N2800/52;;G01N33/6896;;G01N33/92;;G01N2800/2814;;G01N2800/50;;G01N2800/52;;G01N33/6896,G01N33/68,,2,1,168-654-492-788-426,10.1016/j.jalz.2014.06.008;;pmc4329112;;25130657,"FIANDACA ET AL.: ""Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study"", ALZHEIMER'S & DEMENTIA, vol. 11, no. Iss. 6, June 2015 (2015-06-01), pages 600 - 607.e1, XP055237822;;See also references of EP 3146346A4",PENDING
9,US,A1,US 2020/0060543 A1,005-065-708-018-302,2020-02-27,2020,US 201816111248 A,2018-08-24,US 201816111248 A,2018-08-24,METHOD AND SYSTEM FOR BRAIN ATTACK TRIAGE (BAT),"Embodiments herein relate to biosensors and other elements combined in real-time for health applications that acquire health data of an individual from one or more data streams by a first element and integrate these data through a second element that is configured to predict and/or recognize an interruptive health event and then via one or more successive elements alert one or more providers of a possible interruptive health event, enable the providers to propose one or more effective interventions, communicate directly with the individual and providers and/or caregivers, and/or provide confirmation in the event that effective interventions were made. Embodiments also relate to predicting and recognizing brain attack in real-time by acquiring and integrating health data from one or more data streams, interfacing with one or more providers so that they can propose and/or effect one or more effective interventions, and communicating with an affected individual, providers, and/or caregivers.",NAVISALUTE LLC,FEDEROFF HOWARD J;;FRIEDER OPHIR;;FIANDACA MASSIMO S;;JAIN RAMESH,NAVISALUTE LLC (2018-08-20),https://lens.org/005-065-708-018-302,Patent Application,yes,0,1,3,3,0,A61B5/0022;;A61B5/0022;;A61B5/0024;;A61B5/0024;;A61B5/374;;A61B5/374;;A61B5/7257;;A61B5/7257;;A61B5/7264;;A61B5/7264;;A61B5/7275;;A61B5/7275;;A61B5/7282;;A61B5/7282;;G16H80/00;;G16H40/67;;G16H50/20;;G16H50/30;;G16H50/70;;G16H80/00,A61B5/00,,0,0,,,,ACTIVE
10,WO,A3,WO 2020/163493 A3,082-454-704-401-082,2020-10-22,2020,US 2020/0016820 W,2020-02-05,US 201962801271 P,2019-02-05,MATERIALS AND METHODS FOR TREATING A NEURODEGENERATIVE DISEASE,Described herein are materials and methods for the treatment of neurodegenerative diseases by administering a combination of fenofibrate and kaempferol.,UNIV CALIFORNIA;;UNIV GEORGETOWN,FEDEROFF HOWARD;;SUBRAMANIAM SUDHAKAR;;FIANDACA MASSIMO;;MAPSTONE MARK;;SU XIAOMIN,,https://lens.org/082-454-704-401-082,Search Report,yes,4,0,11,11,0,A61K31/216;;A61K31/352;;A61P25/28;;A61K45/06;;A61K36/82;;A61K36/185;;A61P25/28;;A61K31/13;;A61K31/216;;A61K31/27;;A61K31/352;;A61K31/428;;A61K31/4745;;A61K36/185;;A61K36/82,A61K31/496;;A61K31/4164;;A61K45/06,,0,0,,,,PENDING
11,WO,A2,WO 2020/163493 A2,058-238-901-007-176,2020-08-13,2020,US 2020/0016820 W,2020-02-05,US 201962801271 P,2019-02-05,MATERIALS AND METHODS FOR TREATING A NEURODEGENERATIVE DISEASE,Described herein are materials and methods for the treatment of neurodegenerative diseases by administering a combination of fenofibrate and kaempferol.,UNIV CALIFORNIA;;UNIV GEORGETOWN,FEDEROFF HOWARD;;SUBRAMANIAM SUDHAKAR;;FIANDACA MASSIMO;;MAPSTONE MARK;;SU XIAOMIN,,https://lens.org/058-238-901-007-176,Patent Application,yes,0,1,11,11,0,A61K31/216;;A61K31/352;;A61P25/28;;A61K45/06;;A61K36/82;;A61K36/185;;A61P25/28;;A61K31/13;;A61K31/216;;A61K31/27;;A61K31/352;;A61K31/428;;A61K31/4745;;A61K36/185;;A61K36/82,A61K31/353,,0,0,,,,PENDING
12,WO,A9,WO 2020/163493 A9,124-808-577-769-630,2020-11-19,2020,US 2020/0016820 W,2020-02-05,US 201962801271 P,2019-02-05,MATERIALS AND METHODS FOR TREATING A NEURODEGENERATIVE DISEASE,Described herein are materials and methods for the treatment of neurodegenerative diseases by administering a combination of fenofibrate and kaempferol.,UNIV CALIFORNIA;;UNIV GEORGETOWN,FEDEROFF HOWARD;;SUBRAMANIAM SUDHAKAR;;FIANDACA MASSIMO;;MAPSTONE MARK;;SU XIAOMIN,,https://lens.org/124-808-577-769-630,Search Report,yes,0,0,11,11,0,A61K31/216;;A61K31/352;;A61P25/28;;A61K45/06;;A61K36/82;;A61K36/185;;A61P25/28;;A61K31/13;;A61K31/216;;A61K31/27;;A61K31/352;;A61K31/428;;A61K31/4745;;A61K36/185;;A61K36/82,A61K31/4164;;A61K31/496;;A61K45/06,,0,0,,,,PENDING
13,US,A1,US 2021/0298601 A1,174-530-694-992-495,2021-09-30,2021,US 202117202028 A,2021-03-15,US 202117202028 A;;US 201816111248 A,2018-08-24,METHOD AND SYSTEM FOR BRAIN ATTACK TRIAGE (BAT),"Embodiments herein relate to biosensors and other elements combined in real-time for health applications that acquire health data of an individual from one or more data streams by a first element and integrate these data through a second element that is configured to predict and/or recognize an interruptive health event and then via one or more successive elements alert one or more providers of a possible interruptive health event, enable the providers to propose one or more effective interventions, communicate directly with the individual and providers and/or caregivers, and/or provide confirmation in the event that effective interventions were made. Embodiments also relate to predicting and recognizing brain attack in real-time by acquiring and integrating health data from one or more data streams, interfacing with one or more providers so that they can propose and/or effect one or more effective interventions, and communicating with an affected individual, providers, and/or caregivers.",NAVISALUTE LLC,FEDEROFF HOWARD J;;FRIEDER OPHIR;;FIANDACA MASSIMO S;;JAIN RAMESH,NAVISALUTE LLC (2018-08-20),https://lens.org/174-530-694-992-495,Patent Application,yes,0,0,3,3,0,A61B5/0022;;A61B5/0022;;A61B5/0024;;A61B5/0024;;A61B5/374;;A61B5/374;;A61B5/7257;;A61B5/7257;;A61B5/7264;;A61B5/7264;;A61B5/7275;;A61B5/7275;;A61B5/7282;;A61B5/7282;;G16H80/00;;G16H40/67;;G16H50/20;;G16H50/30;;G16H50/70;;G16H80/00,A61B5/00,,0,0,,,,PENDING
14,US,B2,US 10945604 B2,181-908-860-780-603,2021-03-16,2021,US 201816111248 A,2018-08-24,US 201816111248 A,2018-08-24,Method and system for brain attack triage (BAT),"Embodiments herein relate to biosensors and other elements combined in real-time for health applications that acquire health data of an individual from one or more data streams by a first element and integrate these data through a second element that is configured to predict and/or recognize an interruptive health event and then via one or more successive elements alert one or more providers of a possible interruptive health event, enable the providers to propose one or more effective interventions, communicate directly with the individual and providers and/or caregivers, and/or provide confirmation in the event that effective interventions were made. Embodiments also relate to predicting and recognizing brain attack in real-time by acquiring and integrating health data from one or more data streams, interfacing with one or more providers so that they can propose and/or effect one or more effective interventions, and communicating with an affected individual, providers, and/or caregivers.",NAVISALUTE LLC,FEDEROFF HOWARD J;;FRIEDER OPHIR;;FIANDACA MASSIMO S;;JAIN RAMESH,NAVISALUTE LLC (2018-08-20),https://lens.org/181-908-860-780-603,Granted Patent,yes,1,2,3,3,0,A61B5/0022;;A61B5/0022;;A61B5/0024;;A61B5/0024;;A61B5/374;;A61B5/374;;A61B5/7257;;A61B5/7257;;A61B5/7264;;A61B5/7264;;A61B5/7275;;A61B5/7275;;A61B5/7282;;A61B5/7282;;G16H80/00;;G16H40/67;;G16H50/20;;G16H50/30;;G16H50/70;;G16H80/00,A61B5/00;;G16H80/00,,0,0,,,,ACTIVE
15,WO,A1,WO 2015/184107 A1,070-940-351-319-638,2015-12-03,2015,US 2015/0032910 W,2015-05-28,US 201462003666 P;;US 201462004357 P,2014-05-28,GENETIC MARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing the gene expression profile from peripheral blood leukocytes taken from the subject and comparing the value of the subject's gene expression profile with the value of a normal gene expression profile. A change in the value of the subject's gene expression profile, above or below normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;GUSEV YURIY;;FEDEROFF HOWARD J,,https://lens.org/070-940-351-319-638,Patent Application,yes,9,2,6,6,0,C12Q2600/118;;C12Q2600/158;;C12Q2600/16;;C12Q1/6876;;C12Q1/6883;;C12Q2600/118;;C12Q2600/158;;C12Q2600/16;;C12Q1/6876;;C12Q1/6883,C12Q1/68,,16,13,078-854-653-613-883;;106-443-367-647-270;;006-539-454-986-562;;015-393-609-508-491;;068-861-156-686-275;;112-133-786-248-745;;020-858-712-838-577;;000-262-119-070-701;;092-007-236-091-818;;019-607-021-091-564;;064-290-159-063-004;;127-134-528-683-700;;027-637-887-931-488,10.1093/bioinformatics/btp616;;19910308;;pmc2796818;;16939790;;10.1016/s0076-6879(06)11009-5;;10.1093/bioinformatics/btg290;;14594725;;pmc2938201;;10.1093/nar/gkq603;;20601685;;10.1023/a:1012487302797;;pmc3068975;;10.1186/1471-2105-12-77;;21414208;;10.1214/09-ss054;;10.1080/01621459.1984.10478083;;10.1038/nm.3466;;pmc5360460;;24608097;;16234316;;10.1093/bioinformatics/bti724;;10.1111/j.1541-0420.2008.01015.x;;18363775;;10.1111/j.2517-6161.1996.tb02080.x;;10.18637/jss.v033.i01;;pmc2929880;;20808728,"LUNNON ET AL., JOURNAL OF ALZHEIMER'S DISEASE, vol. 33, no. 3, 2013, pages 737 - 753;;ROBINSON, M.D. ET AL., BIOINFORMATICS, vol. 26, 2010, pages 139 - 140;;SAEED, A.I. ET AL., METHODS ENZYMOL, vol. 411, 2006, pages 134 - 193;;JIMENEZ-MARIN, A. ET AL., BMC PROCEEDINGS, vol. 3, no. 4, 2009, pages 6;;NIKITIN, A. ET AL., BIOINFORMATICS, vol. 19, 2003, pages 2155 - 2157;;WANG, K. ET AL., NUCLEIC ACIDS RES, vol. 38, 2010, pages e164;;GUYON, I. ET AL., MACHINE LEARNING, vol. 46, 2002, pages 389 - 422;;ROBIN,X. ET AL., BMC BIOINFORMATICS, vol. 12, 2011, pages 77;;ARLOT, SCELLISE, A., STATISTICS SURVEYS, vol. 4, 2010, pages 40 - 79;;PICARD, R.COOK, R., JOURNAL OF THE AMERICAN STATISTICAL SOIETY, vol. 79, 1984, pages 575 - 583;;MAPSTONE, M. ET AL., NAT MED., vol. 20, no. 4, 2014, pages 415 - 418;;MA, S.HUANG, J., BIOINFORMATICS, vol. 21, 2005, pages 4356 - 4362;;LIU, Z.TAN, M., BIOMETRICS, vol. 64, 2008, pages 1155 - 1161;;TIBSHIRANI, R., JOURNAL OF THE ROYAL STATISTICAL SOCIETY, SERIES B (METHODOLOGICAL, vol. 58, 1996, pages 267 - 288;;HASTIE, T. ET AL.: ""The Elements of Statistical Learning; Data Mining, Inference, and Prediction"", 2008, SPRINGER-VERLAG;;FRIEDMAN, J. ET AL., JOURNAL OF STATISTICAL SOFTWARE, vol. 33, 2010, pages 1 - 22",PENDING
16,EP,B1,EP 3149208 B1,000-896-057-745-957,2021-11-10,2021,EP 15800324 A,2015-05-28,US 201462003666 P;;US 201462004357 P;;US 2015/0032910 W,2014-05-28,GENETIC MARKERS FOR MEMORY LOSS,,UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;GUSEV YURIY;;FEDEROFF HOWARD J,,https://lens.org/000-896-057-745-957,Granted Patent,yes,9,0,6,6,0,C12Q2600/118;;C12Q2600/158;;C12Q2600/16;;C12Q1/6876;;C12Q1/6883;;C12Q2600/118;;C12Q2600/158;;C12Q2600/16;;C12Q1/6876;;C12Q1/6883,C12Q1/6876;;C12Q1/6883,,3,0,,,"DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2013, LUNNON KATIE ET AL: ""A Blood Gene Expression Marker of Early Alzheimer's Disease"", XP55174560, Database accession no. PREV201300175294 & JOURNAL OF ALZHEIMER'S DISEASE, vol. 33, no. 3, 2013, pages 737-753, ISSN: 1387-2877(print), DOI: 10.3233/JAD-2012-121363;;ROED L ET AL: ""Prediction of Mild Cognitive Impairment that Evolves into Alzheimer's Disease Dementia within Two Years using a Gene Expression Signature in Blood: A Pilot Study"", JOURNAL OF ALZHEIMER'S DISEASE, IOS PRESS, NL, 11 March 2013 (2013-03-11), pages 1-11, XP002694761, ISSN: 1387-2877, DOI: 10.3233/JAD-122404;;None",ACTIVE
17,US,A1,US 2017/0183733 A1,038-536-709-732-079,2017-06-29,2017,US 201515312856 A,2015-05-28,US 201515312856 A;;US 201462003666 P;;US 201462004357 P;;US 2015/0032910 W,2014-05-28,GENETIC MARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing the gene expression profile from peripheral blood leukocytes taken from the subject and comparing the value of the subject's gene expression profile with the value of a normal gene expression profile. A change in the value of the subject's gene expression profile, above or below normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;GUSEV YURIY;;FEDEROFF HOWARD J,GEORGETOWN UNIVERSITY (2015-06-15);;UNIVERSITY OF ROCHESTER (2015-07-01),https://lens.org/038-536-709-732-079,Patent Application,yes,0,0,6,6,0,C12Q1/6883;;C12Q1/6883;;C12Q1/6876;;C12Q1/6876;;C12Q2600/118;;C12Q2600/118;;C12Q2600/158;;C12Q2600/158;;C12Q2600/16;;C12Q2600/16,C12Q1/68,,0,0,,,,ACTIVE
18,EP,A4,EP 3149208 A4,000-844-079-416-682,2017-12-20,2017,EP 15800324 A,2015-05-28,US 201462003666 P;;US 201462004357 P;;US 2015/0032910 W,2014-05-28,GENETIC MARKERS FOR MEMORY LOSS,,UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;GUSEV YURIY;;FEDEROFF HOWARD J,,https://lens.org/000-844-079-416-682,Search Report,no,5,0,6,6,0,C12Q1/6883;;C12Q1/6883;;C12Q1/6876;;C12Q1/6876;;C12Q2600/118;;C12Q2600/118;;C12Q2600/158;;C12Q2600/158;;C12Q2600/16;;C12Q2600/16,C12Q1/68,,3,1,097-963-508-055-602,10.3233/jad-122404;;23478308,"DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2013, LUNNON KATIE ET AL: ""A Blood Gene Expression Marker of Early Alzheimer's Disease"", XP055174560, Database accession no. PREV201300175294;;ROED L ET AL: ""Prediction of Mild Cognitive Impairment that Evolves into Alzheimer's Disease Dementia within Two Years using a Gene Expression Signature in Blood: A Pilot Study"", JOURNAL OF ALZHEIMER'S DISEASE, IOS PRESS, NL, 11 March 2013 (2013-03-11), pages 1 - 11, XP002694761, ISSN: 1387-2877, DOI: 10.3233/JAD-122404;;See also references of WO 2015184107A1",ACTIVE
19,US,B2,US 10718021 B2,002-916-497-925-124,2020-07-21,2020,US 201515312856 A,2015-05-28,US 201515312856 A;;US 201462003666 P;;US 201462004357 P;;US 2015/0032910 W,2014-05-28,Genetic markers for memory loss,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing the gene expression profile from peripheral blood leukocytes taken from the subject and comparing the value of the subject's gene expression profile with the value of a normal gene expression profile. A change in the value of the subject's gene expression profile, above or below normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;GUSEV YURIY;;FEDEROFF HOWARD J,GEORGETOWN UNIVERSITY (2015-06-15);;UNIVERSITY OF ROCHESTER (2015-07-01),https://lens.org/002-916-497-925-124,Granted Patent,yes,4,0,6,6,0,C12Q1/6883;;C12Q1/6883;;C12Q1/6876;;C12Q1/6876;;C12Q2600/118;;C12Q2600/118;;C12Q2600/158;;C12Q2600/158;;C12Q2600/16;;C12Q2600/16,A61K38/00;;C12Q1/68;;C12Q1/6876;;C12Q1/6883;;G01N33/567,,1,0,,,"International Search Report issued in the corresponding International Application No. PCT/US2015/032910 dated Sep. 1, 2015.",ACTIVE
20,EP,A1,EP 3149208 A1,022-980-511-214-516,2017-04-05,2017,EP 15800324 A,2015-05-28,US 201462003666 P;;US 201462004357 P;;US 2015/0032910 W,2014-05-28,GENETIC MARKERS FOR MEMORY LOSS,,UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;GUSEV YURIY;;FEDEROFF HOWARD J,,https://lens.org/022-980-511-214-516,Patent Application,yes,0,0,6,6,0,C12Q1/6883;;C12Q1/6883;;C12Q1/6876;;C12Q1/6876;;C12Q2600/118;;C12Q2600/118;;C12Q2600/158;;C12Q2600/158;;C12Q2600/16;;C12Q2600/16,C12Q1/68,,0,0,,,,ACTIVE
21,CN,A,CN 114007607 A,140-735-485-092-162,2022-02-01,2022,CN 202080027379 A,2020-02-05,US 201962801271 P;;US 2020/0016820 W,2019-02-05,MATERIALS AND METHODS FOR TREATING A NEURODEGENERATIVE DISEASE,Described herein are materials and methods for the treatment of neurodegenerative diseases by administering a combination of fenofibrate and kaempferol.,UNIV CALIFORNIA;;UNIV GEORGETOWN,FEDEROFF HOWARD;;SUBRAMANIAM SUDHAKAR;;FIANDACA MASSIMO;;MAPSTONE MARK E;;SU XIAOMIN,,https://lens.org/140-735-485-092-162,Patent Application,no,0,1,11,11,0,A61K31/216;;A61K31/352;;A61P25/28;;A61K45/06;;A61K36/82;;A61K36/185;;A61P25/28;;A61K31/13;;A61K31/216;;A61K31/27;;A61K31/352;;A61K31/428;;A61K31/4745;;A61K36/185;;A61K36/82,A61K31/4164;;A61K31/496;;A61K45/06,,0,0,,,,PENDING
22,CA,A1,CA 2965287 A1,001-175-131-549-740,2015-04-30,2015,CA 2965287 A,2014-10-21,US 201361893762 P;;US 2014/0061578 W,2013-10-21,BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and comparing the value of the subject's lipidomic profile with the value of a normal lipidomic profile. A decrease in the value of the subject's lipidomic profile over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;MAPSTONE MARK E;;CHEEMA AMRITA K;;FIANDACA MASSIMO S,,https://lens.org/001-175-131-549-740,Patent Application,no,0,0,8,8,0,G01N2570/00;;G01N2800/2814;;G01N33/92;;A61P25/28;;G01N2570/00;;G01N2800/2814;;G01N33/92;;G01N2405/00;;G01N2405/04;;G01N2800/2821;;G01N2800/52,,,0,0,,,,DISCONTINUED
23,EP,A1,EP 3137900 A1,057-333-334-859-872,2017-03-08,2017,EP 15785913 A,2015-04-30,US 201461986555 P;;US 2015/0028550 W,2014-04-30,METABOLIC AND GENETIC BIOMARKERS FOR MEMORY LOSS,,UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;MAPSTONE MARK E;;CHEEMA AMRITA K;;FIANDACA MASSIMO S,,https://lens.org/057-333-334-859-872,Patent Application,yes,0,0,4,4,0,C12Q1/6883;;C12Q1/6883;;C12Q2600/158;;C12Q2600/158;;G01N33/92;;G01N33/92;;G01N2570/00;;G01N2570/00;;G01N2800/2814;;G01N2800/2814;;G01N2800/52;;G01N2800/52,G01N33/50,,0,0,,,,DISCONTINUED
24,AU,A1,AU 2014/340292 A1,066-256-297-307-496,2016-06-09,2016,AU 2014/340292 A,2014-10-21,US 201361893762 P;;US 2014/0061578 W,2013-10-21,Biomarkers for memory loss,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and comparing the value of the subject's lipidomic profile with the value of a normal lipidomic profile. A decrease in the value of the subject's lipidomic profile over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN,FEDEROFF HOWARD J;;MAPSTONE MARK E;;CHEEMA AMRITA K;;FIANDACA MASSIMO S,,https://lens.org/066-256-297-307-496,Patent Application,no,0,0,8,8,0,G01N2570/00;;G01N2800/2814;;G01N33/92;;A61P25/28;;G01N2570/00;;G01N2800/2814;;G01N33/92;;G01N2405/00;;G01N2405/04;;G01N2800/2821;;G01N2800/52,A61P25/28,,0,0,,,,DISCONTINUED
25,US,B2,US 10900980 B2,130-550-814-290-386,2021-01-26,2021,US 201615575115 A,2016-05-18,US 201615575115 A;;US 201562163034 P;;US 201562194223 P;;US 2016/0033100 W,2015-05-18,Metabolic biomarkers for memory loss,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;FIANDACA MASSIMO S;;CHEEMA AMRITA K;;MAPSTONE MARK E,GEORGETOWN UNIVERSITY (2018-01-08);;UNIVERSITY OF ROCHESTER (2018-01-08),https://lens.org/130-550-814-290-386,Granted Patent,yes,4,2,5,9,0,G01N33/6896;;G01N33/6896;;G01N33/92;;G01N2405/04;;G01N2800/2821;;G01N2800/50;;G01N2800/60,A61K38/00;;C12Q1/68;;G01N33/567;;G01N33/68;;G01N33/92,,3,2,064-884-460-165-745;;074-073-998-065-31X,24139043;;10.1016/j.neuron.2013.08.013;;pmc3820368;;25562043;;10.1016/j.phrp.2014.10.002;;pmc4281626,"International Search Report issued in corresponding International Patent Application No. PCT/US2016/033100 dated Aug. 30, 2016.;;Ruzzo et al., “Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy,” Neuron, 80: 429-441 (2013).;;Kim et al., “Aging-related changes in mouse serum glycerophospholipid profiles,” Osong Public Health and Research Perspectives, 5: 345-350 (2014).",ACTIVE
26,EP,A4,EP 3060305 A4,041-900-866-037-56X,2017-04-12,2017,EP 14855189 A,2014-10-21,US 201361893762 P;;US 2014/0061578 W,2013-10-21,BIOMARKERS FOR MEMORY LOSS,,UNIV GEORGETOWN,FEDEROFF HOWARD J;;MAPSTONE MARK E;;CHEEMA AMRITA K;;FIANDACA MASSIMO S,,https://lens.org/041-900-866-037-56X,Search Report,no,1,0,8,8,0,G01N2570/00;;G01N2800/2814;;G01N33/92;;A61P25/28;;G01N2570/00;;G01N2800/2814;;G01N33/92;;G01N2405/00;;G01N2405/04;;G01N2800/2821;;G01N2800/52,A61P25/28,,3,2,000-769-559-625-777;;092-007-236-091-818,pmc3136924;;21779331;;10.1371/journal.pone.0021643;;10.1038/nm.3466;;pmc5360460;;24608097,"XIANLIN HAN ET AL: ""Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics"", PLOS ONE, vol. 6, no. 7, 1 July 2011 (2011-07-01), pages e21643, XP055351379, DOI: 10.1371/journal.pone.0021643;;MARK MAPSTONE ET AL: ""Plasma phospholipids identify antecedent memory impairment in older adults"", NATURE MEDICINE, vol. 20, no. 4, 1 January 2014 (2014-01-01), pages 415 - 418, XP055351904, ISSN: 1078-8956, DOI: 10.1038/nm.3466;;See also references of WO 2015061317A1",ACTIVE
27,US,B2,US 10578629 B2,187-410-167-677-341,2020-03-03,2020,US 201615134976 A,2016-04-21,US 201615134976 A;;US 2014/0061578 W;;US 201361893762 P,2013-10-21,Biomarkers for memory loss,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and comparing the value of the subject's lipidomic profile with the value of a normal lipidomic profile. A decrease in the value of the subject's lipidomic profile over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;MAPSTONE MARK E;;CHEEMA AMRITA K;;FIANDACA MASSIMO S,GEORGETOWN UNIVERSITY (2014-10-29);;UNIVERSITY OF ROCHESTER (2015-07-01),https://lens.org/187-410-167-677-341,Granted Patent,yes,3,0,8,8,0,G01N2570/00;;G01N2800/2814;;G01N33/92;;A61P25/28;;G01N2570/00;;G01N2800/2814;;G01N33/92;;G01N2405/00;;G01N2405/04;;G01N2800/2821;;G01N2800/52,G01N33/92,,7,5,000-769-559-625-777;;066-844-241-358-05X;;076-775-818-418-384;;037-239-334-542-107;;022-763-156-198-572,pmc3136924;;21779331;;10.1371/journal.pone.0021643;;9562266;;10.1016/s0022-510x(97)00314-6;;21543199;;pmc3161165;;10.1016/j.plefa.2011.04.021;;10.1074/jbc.m111.274142;;pmc3268426;;22134919;;20117236;;10.1016/j.bbalip.2010.01.010;;pmc2886180,"Han et al., PLoS ONE, 6(7):e21643, Jul. 2011.;;Jones et al., Progress in Lipid Research, 49: 61-75, published online Aug. 2009.;;Rubio et al., J Neurolog Sci., 155:192-195, 1998.;;Astarita et al., “Towards a whole-body systems [multi-organ] lipidomics in Alzheimer's disease,” Prostaglandins Leukot Essent Fatty Acids, 85(5):197-203 (2011).;;Chan et al., “Comparative lipidomic analysis of mouse and human brain with Alzheimer disease,” J. Biol. Chem., 287(4):2678-2688 (2012).;;Han et al., “Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease,” Biochim Biophys Acta., 1801(8):774-783 (2010).;;International Search Report and Written Opinion issued in a corresponding International Application No. PCT/US2014/061578 dated Feb. 5, 2015.",ACTIVE
28,EP,A4,EP 3137900 A4,039-504-764-514-971,2018-01-03,2018,EP 15785913 A,2015-04-30,US 201461986555 P;;US 2015/0028550 W,2014-04-30,METABOLIC AND GENETIC BIOMARKERS FOR MEMORY LOSS,,UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;MAPSTONE MARK E;;CHEEMA AMRITA K;;FIANDACA MASSIMO S,,https://lens.org/039-504-764-514-971,Search Report,no,2,0,4,4,0,C12Q1/6883;;C12Q1/6883;;C12Q2600/158;;C12Q2600/158;;G01N33/92;;G01N33/92;;G01N2570/00;;G01N2570/00;;G01N2800/2814;;G01N2800/2814;;G01N2800/52;;G01N2800/52,G01N33/50;;C12Q1/68;;G01N33/68;;G01N33/92,,2,1,092-007-236-091-818,10.1038/nm.3466;;pmc5360460;;24608097,"MARK MAPSTONE ET AL: ""Plasma phospholipids identify antecedent memory impairment in older adults"", NATURE MEDICINE, vol. 20, no. 4, 9 March 2014 (2014-03-09), pages 415 - 418, XP055351904, ISSN: 1078-8956, DOI: 10.1038/nm.3466;;See also references of WO 2015168426A1",DISCONTINUED
29,US,B2,US 11808774 B2,075-408-504-305-466,2023-11-07,2023,US 202117157932 A,2021-01-25,US 202117157932 A;;US 201715575115 A;;US 2016/0033100 W;;US 201562163034 P;;US 201562194223 P,2015-05-18,Metabolic biomarkers for memory loss,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;FIANDACA MASSIMO S;;CHEEMA AMRITA K;;MAPSTONE MARK E,GEORGETOWN UNIVERSITY (2018-01-29);;UNIVERSITY OF ROCHESTER (2018-01-08),https://lens.org/075-408-504-305-466,Granted Patent,yes,19,0,5,9,0,G01N33/6896;;G01N33/6896;;G01N33/92;;G01N2405/04;;G01N2800/2821;;G01N2800/50;;G01N2800/60,G01N33/92;;G01N33/68,,18,18,064-884-460-165-745;;074-073-998-065-31X;;076-775-818-418-384;;037-239-334-542-107;;022-763-156-198-572;;000-769-559-625-777;;048-824-594-633-263;;066-844-241-358-05X;;092-007-236-091-818;;023-137-451-973-365;;010-211-322-795-751;;004-387-952-367-614;;046-579-746-715-155;;010-184-521-660-138;;061-260-074-654-837;;021-426-045-667-387;;049-393-259-293-948;;000-456-556-730-283,24139043;;10.1016/j.neuron.2013.08.013;;pmc3820368;;25562043;;10.1016/j.phrp.2014.10.002;;pmc4281626;;21543199;;pmc3161165;;10.1016/j.plefa.2011.04.021;;10.1074/jbc.m111.274142;;pmc3268426;;22134919;;20117236;;10.1016/j.bbalip.2010.01.010;;pmc2886180;;pmc3136924;;21779331;;10.1371/journal.pone.0021643;;19720082;;10.1016/j.plipres.2009.08.004;;9562266;;10.1016/s0022-510x(97)00314-6;;10.1038/nm.3466;;pmc5360460;;24608097;;9482271;;10.1023/a:1022457605436;;15465626;;10.1016/j.neurobiolaging.2004.02.016;;26617567;;pmc4642213;;10.3389/fneur.2015.00237;;16895547;;10.1111/j.1440-1681.2006.04425.x;;pmc4947451;;26806385;;10.1016/j.jalz.2015.12.008;;10.1074/mcp.m500207-mcp200;;16199891;;pmc5471778;;10.1159/000466688;;28626469;;19079617;;pmc2600464;;pmc5985530;;10.1016/j.neurobiolaging.2016.11.007;;27939698,"Elizabeth K. Ruzzo, et al., Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy, Neuron, 2013, pp. 429-441, vol. 80, No. 2.;;Seungwoo Kim, et al., Aging-related changes in mouse serum glycerophospholipid profiles, Osong Public Health and Research Perspectives, 2014, pp. 345-350, vol. 5, No. 6.;;Giuseppe Astarita and Daniele Piomelli, Towards a whole-body systems [multi-organ] lipidomics in Alzheimer's disease, Prostaglandins, Leukotrienes, and Essential Fatty Acids, 2011, pp. 197-203, vol. 85, No. 5.;;Robin B. Chan, et al., Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer Disease, Journal of Biological Chemistry, 2012, pp. 2678-2688, vol. 287, No. 4.;;Xianlin Han, Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease, Biochimica et Biophysica Acta, 2010, pp. 774-783, vol. 1801, No. 8.;;Xianlin Han, et al., Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics, PLoS One, 2011, p. e21643, vol. 6, No. 7.;;Lauren L. Jones, et al., Acylcarnitines: role in brain, Progress in Lipid Research, 2010, pp. 61-75, vol. 49, issue 1.;;Juan Carlos Rubio, et al., Cerebrospinal fluid carnitine levels in patients with Alzheimer's disease, Journal of Neurological Sciences, 1998, pp. 192-195, vol. 155.;;Mark Mapstone, et al., Plasma phospholipids identify antecedent memory impairment in older adults, Nature Medicine, 2014, pp. 415-418, vol. 20.;;M. Renuka Prasad et al., Regional membrane phospholipid alterations in Alzheimer's disease, Neurochemical Research, 1998, pp. 81-88, vol. 23, No. 1.;;Anna Walter, et al., Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients, Neurobiology of Aging, 2004, pp. 1299-1303, vol. 25.;;Massimo S. Fiandaca, et al., Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer's disease, Frontiers in Neurology, 2015, pp. 1-13, vol. 6.;;Abdulhakeem A. Al-Majed, et al., Carnitine esters prevent oxidative stress damage and energy depletion following transient forebrain ischaemia in the rat hippocampus, Clinical and Experimental Pharmacology and Physiology, 2006, pp. 725-733, vol. 33.;;Ramon Casanova, et al., Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals, Alzheimer's & Dementia, 2016, pp. 815-822, vol. 12.;;Yan Hu et al., Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid, Molecular & Cellular Proteomics, 2005, pp. 2000-2009, vol. 4.;;Gaetano Corso, et al., Serum amino acid profiles in normal subjects and in patients with or at risk of Alzheimer dementia, Dementia and Geriatric Cognitive Disorders, 2017, pp. 143-159, vol. 7.;;Jing Yi, et al., L-arginine and Alzheimer's disease, International Journal of Clinical and Experimental Pathology, 2009, pp. 211-238, vol. 2, No. 3.;;Mark Mapstone, et al., What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer's disease, Neurobiology of Aging, 2017, pp. 148-155, vol. 51.",ACTIVE
30,US,A1,US 2021/0285973 A1,122-419-944-678-844,2021-09-16,2021,US 202117157932 A,2021-01-25,US 202117157932 A;;US 201715575115 A;;US 2016/0033100 W;;US 201562163034 P;;US 201562194223 P,2015-05-18,METABOLIC BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's meta-bolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;FIANDACA MASSIMO S;;CHEEMA AMRITA K;;MAPSTONE MARK E,GEORGETOWN UNIVERSITY (2018-01-29);;UNIVERSITY OF ROCHESTER (2018-01-08),https://lens.org/122-419-944-678-844,Patent Application,yes,1,0,5,9,0,G01N33/6896;;G01N33/6896;;G01N33/92;;G01N2405/04;;G01N2800/2821;;G01N2800/50;;G01N2800/60,G01N33/92;;G01N33/68,,0,0,,,,ACTIVE
31,WO,A1,WO 2015/168426 A1,078-696-379-463-008,2015-11-05,2015,US 2015/0028550 W,2015-04-30,US 201461986555 P,2014-04-30,METABOLIC AND GENETIC BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and also analyzing the gene expression profile from leukocytes and comparing the value of the subject's biomarker profile (lipidomic profile plus gene expression profile) with the value of a normal biomarker profile. A change in the value of the subject's biomarker profile, including a change in the subject's biomarker profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;MAPSTONE MARK E;;CHEEMA AMRITA K;;FIANDACA MASSIMO S,,https://lens.org/078-696-379-463-008,Patent Application,yes,5,4,4,4,0,C12Q1/6883;;C12Q1/6883;;C12Q2600/158;;C12Q2600/158;;G01N33/92;;G01N33/92;;G01N2570/00;;G01N2570/00;;G01N2800/2814;;G01N2800/2814;;G01N2800/52;;G01N2800/52,G01N33/50,,4,3,092-007-236-091-818;;041-675-405-786-260;;020-935-196-972-548,10.1038/nm.3466;;pmc5360460;;24608097;;10.3233/jad-2011-101881;;21321390;;22785402;;10.3233/jad-2012-120637,"MAPSTONE ET AL.: ""Plasma phospholipids identify antecedent memory impairment in older adults"", NATURE MEDICINE, vol. 20, 9 March 2014 (2014-03-09), pages 415 - 418, XP055129668;;ARISI ET AL.: ""Gene Expression Biomarkers in the Brain of a Mouse Model for Alzheimer's Disease: Mining of Microarray Data by Logic Classification and Feature Selection"", JOURNAL OF ALZHEIMER'S DISEASE, vol. 24, 2011, pages 721 - 738, XP055234239;;FEHLBAUM-BEURDELEY ET AL.: ""Validation of AclarusDm, a Blood-Based Transcriptomic Signature for the Diagnosis of Alzheimer's Disease"", JOURNAL OF ALZHEIMER'S DISEASE, vol. 32, no. Iss. 1, 2012, pages 169181, XP008165787;;See also references of EP 3137900A4",PENDING
32,WO,A1,WO 2018/144816 A1,188-183-860-219-305,2018-08-09,2018,US 2018/0016590 W,2018-02-02,US 201762453742 P,2017-02-02,METABOLIC BIOMARKERS FOR COGNITIVE ABILITY,"The present invention relates to methods of determining if a subject has a decreased risk of suffering from future memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has a decreased risk of suffering from future memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,MAPSTONE MARK E;;FEDEROFF HOWARD J;;FIANDACA MASSIMO S;;CHEEMA AMRITA K,,https://lens.org/188-183-860-219-305,Patent Application,yes,1,1,3,3,0,A61P25/28;;G01N33/5308;;G01N33/6896;;G01N2800/2814;;G01N2800/50;;G01N2800/52;;G01N33/6896;;G01N2560/00;;G01N2800/2814;;G01N2800/50;;G01N2800/52,G01N33/48;;A61P25/28;;G01N33/50,,4,3,000-456-556-730-283;;092-007-236-091-818;;021-426-045-667-387,pmc5985530;;10.1016/j.neurobiolaging.2016.11.007;;27939698;;10.1038/nm.3466;;pmc5360460;;24608097;;pmc5471778;;10.1159/000466688;;28626469,"MAPSTONE, M ET AL.: ""What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer's disease"", NEUROBIOLOGY OF AGING, vol. 51, 21 November 2016 (2016-11-21), pages 148 - 155, XP055529840;;MAPSTONE, M ET AL.: ""Plasma phospholipids identify antecedent memory impairment in older adults"", NATURE MEDICINE, vol. 20, no. 4, 9 March 2014 (2014-03-09), pages 415 - 418, XP055351904;;YI, J ET AL.: ""L-Arginine and Alzheimer's Disease"", INTERNATIONAL JOURNAL OF CLINICAL & EXPERIMENTAL PATHOLOGY, vol. 2, no. 3, 2 October 2008 (2008-10-02), pages 211 - 238, XP055529848;;CORSO, G ET AL.: ""Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia"", DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA., vol. 7, no. 1, 4 May 2017 (2017-05-04), pages 143 - 159, XP055529855",PENDING
33,WO,A3,WO 2023/183594 A3,031-720-878-108-117,2024-01-18,2024,US 2023/0016270 W,2023-03-24,US 202263323830 P;;US 202263326236 P;;US 202263341841 P;;US 202263393196 P;;US 202363438164 P,2022-03-25,METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE,"Aspects of the disclosure relate to compositions and methods useful for treating Parkinson's disease. In some embodiments, the disclosure provides a method for treating Parkinson's disease comprising administration of a viral vector comprising a GDNF nucleic acid sequence. In some embodiments, administration is locally to the subject putamen. In some embodiments, administration is systemically, e.g., via the viral vector comprising a modified viral capsid, such as for preferentially targeting cells in the CNS or PNS.",ASKLEPIOS BIOPHARMACEUTICAL INC,BANKIEWICZ KRYSTOF S;;KELLS ADRIAN P;;VAN LAAR AMBER;;FIANDACA MASSIMO S,,https://lens.org/031-720-878-108-117,Search Report,yes,1,0,2,2,64,C12N15/86;;C12N2750/14143;;A61K48/005;;A61K48/0075;;C07K14/4705,A61K48/00;;A61P25/16;;C12N15/86,,6,5,013-243-907-979-973;;031-114-632-149-445;;048-563-040-470-615;;145-769-970-331-363;;089-193-612-206-505,31145831;;pmc6642028;;10.1002/mds.27724;;19254173;;pmc2725183;;10.1089/hum.2008.201;;10.1038/news030324-12;;12669033;;10.1038/nm850;;16084732;;10.1016/j.nbd.2005.06.015;;34887588;;10.1038/s41593-021-00969-4;;10.3410/f.741298403.793591394,"HEISS JOHN D., LUNGU CODRIN, HAMMOUD DIMA A., HERSCOVITCH PETER, EHRLICH DEBRA J., ARGERSINGER DAVIS P., SINHARAY SANHITA, SCOTT G: ""Trial of magnetic resonance–guided putaminal gene therapy for advanced Parkinson's disease"", MOVEMENT DISORDERS, RAVEN PRESS, NEW YORK, NY, US, vol. 34, no. 7, 1 July 2019 (2019-07-01), US , pages 1073 - 1078, XP093131075, ISSN: 0885-3185, DOI: 10.1002/mds.27724;;EBERLING JAMIE L., KELLS ADRIAN P., PIVIROTTO PHILIP, BEYER JANINE, BRINGAS JOHN, FEDEROFF HOWARD J., FORSAYETH JOHN, BANKIEWICZ K: ""Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys"", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, GB, vol. 20, no. 5, 1 May 2009 (2009-05-01), GB , pages 511 - 518, XP093131077, ISSN: 1043-0342, DOI: 10.1089/hum.2008.201;;DATABASE GenBank NCBI; ANONYMOUS : ""Homo sapiens glial cell derived neurotrophic factor, mRNA (cDNA clone MGC:95398 IMAGE:7216973"", XP093131080;;GILL, SS ET AL.: ""Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease"", NATURE MEDICINE, vol. 9, no. 5, May 2003 (2003-05-01) - 31 March 2003 (2003-03-31), pages 589 - 595, XP002427989, DOI: 10.1038/nm850;;BRIZARD, M ET AL.: ""Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease"", NEUROBIOLOGY OF DISEASE, vol. 21, no. 1, January 2006 (2006-01-01) - 9 August 2005 (2005-08-09), pages 1, XP024901428, DOI: 10.1016GAMMA.nbd. 2005.06.01 5;;GOERTSEN, D ET AL.: ""AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset"", NATURE NEUROSCIENCE, vol. 25, no. 1, January 2022 (2022-01-01) - 9 December 2021 (2021-12-09), pages 106 - 115, XP037658234, DOI: 10.1038/s41593-021-00969-4",PENDING
34,WO,A1,WO 2015/061317 A1,109-029-190-056-787,2015-04-30,2015,US 2014/0061578 W,2014-10-21,US 201361893762 P,2013-10-21,BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and comparing the value of the subject's lipidomic profile with the value of a normal lipidomic profile. A decrease in the value of the subject's lipidomic profile over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN,FEDEROFF HOWARD J;;MAPSTONE MARK E;;CHEEMA AMRITA K;;FIANDACA MASSIMO S,,https://lens.org/109-029-190-056-787,Patent Application,yes,4,4,8,8,0,G01N2570/00;;G01N2800/2814;;G01N33/92;;A61P25/28;;G01N2570/00;;G01N2800/2814;;G01N33/92;;G01N2405/00;;G01N2405/04;;G01N2800/2821;;G01N2800/52,A61P25/28,,4,4,037-239-334-542-107;;076-775-818-418-384;;022-763-156-198-572;;000-769-559-625-777,10.1074/jbc.m111.274142;;pmc3268426;;22134919;;21543199;;pmc3161165;;10.1016/j.plefa.2011.04.021;;20117236;;10.1016/j.bbalip.2010.01.010;;pmc2886180;;pmc3136924;;21779331;;10.1371/journal.pone.0021643,"CHAN ET AL.: ""Comparative lipidomic analysis of mouse and human brain with Alzheimer disease"", J BIOL CHEM., vol. 287, 1 December 2011 (2011-12-01), pages 2678 - 2688, XP055339718;;ASTARITA ET AL.: ""Towards a whole-body systems [multi-organ) lipidomics in Alzheimer's disease"", PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS., vol. 85, 4 May 2011 (2011-05-04), pages 197 - 203, XP028309053;;HAN ET AL.: ""Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease"", BIOCHIM BIOPHYS ACTA, vol. 1801, 1 February 2010 (2010-02-01), pages 774 - 783, XP027086263;;HAN, X. ET AL., PLOSONE, vol. 6, no. 7, 2011, pages e21643",PENDING
35,US,A1,US 2020/0011881 A1,022-933-252-045-399,2020-01-09,2020,US 201816483260 A,2018-02-02,US 201816483260 A;;US 201762453742 P;;US 2018/0016590 W,2017-02-02,METABOLIC BIOMARKERS FOR COGNITIVE ABILITY,"The present invention relates to methods of determining if a subject has a decreased risk of suffering from future memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has a decreased risk of suffering from future memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,MAPSTONE MARK E;;FEDEROFF HOWARD J;;FIANDACA MASSIMO S;;CHEEMA AMRITA K,GEORGETOWN UNIVERSITY (2019-08-29);;UNIVERSITY OF ROCHESTER (2019-08-12),https://lens.org/022-933-252-045-399,Patent Application,yes,0,0,3,3,0,A61P25/28;;G01N33/5308;;G01N33/6896;;G01N2800/2814;;G01N2800/50;;G01N2800/52;;G01N33/6896;;G01N2560/00;;G01N2800/2814;;G01N2800/50;;G01N2800/52,G01N33/68,,0,0,,,,ACTIVE
36,US,A1,US 2016/0238622 A1,103-237-289-344-461,2016-08-18,2016,US 201615134976 A,2016-04-21,US 201615134976 A;;US 2014/0061578 W;;US 201361893762 P,2013-10-21,BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and comparing the value of the subject's lipidomic profile with the value of a normal lipidomic profile. A decrease in the value of the subject's lipidomic profile over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;MAPSTONE MARK E;;CHEEMA AMRITA K;;FIANDACA MASSIMO S,GEORGETOWN UNIVERSITY (2014-10-29);;UNIVERSITY OF ROCHESTER (2015-07-01),https://lens.org/103-237-289-344-461,Patent Application,yes,0,1,8,8,0,G01N2570/00;;G01N2800/2814;;G01N33/92;;A61P25/28;;G01N2570/00;;G01N2800/2814;;G01N33/92;;G01N2405/00;;G01N2405/04;;G01N2800/2821;;G01N2800/52,G01N33/92,,6,4,066-844-241-358-05X;;000-769-559-625-777;;000-769-559-625-777;;066-844-241-358-05X,9562266;;10.1016/s0022-510x(97)00314-6;;pmc3136924;;21779331;;10.1371/journal.pone.0021643;;pmc3136924;;21779331;;10.1371/journal.pone.0021643;;9562266;;10.1016/s0022-510x(97)00314-6,"Rubio et al., J Neurolog Sci., 155:192-195, 1998;;Han et al., PLoS ONE, 6(7):e21643, July 2011;;Jones et al., Progress in Lipid Research, 49: 61–75, published online August 2009;;Han et al., PLoS ONE, 6(7):e21643, July 2011;;Jones et al., Progress in Lipid Research, 49: 61–75, published online August 2009;;Rubio et al., J Neurolog Sci., 155:192-195, 1998",ACTIVE
37,EP,A1,EP 3060305 A1,109-740-047-385-320,2016-08-31,2016,EP 14855189 A,2014-10-21,US 201361893762 P;;US 2014/0061578 W,2013-10-21,BIOMARKERS FOR MEMORY LOSS,,UNIV GEORGETOWN,FEDEROFF HOWARD J;;MAPSTONE MARK E;;CHEEMA AMRITA K;;FIANDACA MASSIMO S,,https://lens.org/109-740-047-385-320,Patent Application,yes,0,0,8,8,0,G01N2570/00;;G01N2800/2814;;G01N33/92;;A61P25/28;;G01N2570/00;;G01N2800/2814;;G01N33/92;;G01N2405/00;;G01N2405/04;;G01N2800/2821;;G01N2800/52,A61P25/28,,0,0,,,,ACTIVE
38,WO,A1,WO 2016/187317 A1,045-452-633-977-496,2016-11-24,2016,US 2016/0033100 W,2016-05-18,US 201562163034 P;;US 201562194223 P,2015-05-18,METABOLIC BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;FIANDACA MASSIMO S;;CHEEMA AMRITA K;;MAPSTONE MARK E,,https://lens.org/045-452-633-977-496,Patent Application,yes,4,3,5,9,0,G01N33/6896;;G01N33/6896;;G01N33/92;;G01N2405/04;;G01N2800/2821;;G01N2800/50;;G01N2800/60,G01N33/50;;G01J3/00;;G01N33/68;;G01N33/92,,2,2,064-884-460-165-745;;074-073-998-065-31X,24139043;;10.1016/j.neuron.2013.08.013;;pmc3820368;;25562043;;10.1016/j.phrp.2014.10.002;;pmc4281626,"RUZZO ET AL.: ""Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy"", NEURON, vol. 80, no. 2, 16 October 2013 (2013-10-16), pages 429 - 441, XP028757374;;KIM ET AL.: ""Aging-related changes in mouse serum glycerophospholipid profiles"", OSONG PUBLIC HEALTH RES PERSPECT, vol. 5, no. 6, December 2014 (2014-12-01), pages 345 - 350, XP055330989",PENDING
39,US,A1,US 2018/0149665 A1,167-923-369-607-868,2018-05-31,2018,US 201615575115 A,2016-05-18,US 201615575115 A;;US 201562163034 P;;US 201562194223 P;;US 2016/0033100 W,2015-05-18,Metabolic Biomarkers for Memory Loss,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;FIANDACA MASSIMO S;;CHEEMA AMRITA K;;MAPSTONE MARK E,GEORGETOWN UNIVERSITY (2018-01-08);;UNIVERSITY OF ROCHESTER (2018-01-08),https://lens.org/167-923-369-607-868,Patent Application,yes,0,2,5,9,0,G01N33/6896;;G01N33/6896;;G01N33/92;;G01N2405/04;;G01N2800/2821;;G01N2800/50;;G01N2800/60,G01N33/92,,0,0,,,,ACTIVE
40,US,B2,US 11280797 B2,036-881-490-811-032,2022-03-22,2022,US 201816483260 A,2018-02-02,US 201816483260 A;;US 201762453742 P;;US 2018/0016590 W,2017-02-02,Metabolic biomarkers for cognitive ability,"The present invention relates to methods of determining if a subject has a decreased risk of suffering from future memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has a decreased risk of suffering from future memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,MAPSTONE MARK E;;FEDEROFF HOWARD J;;FIANDACA MASSIMO S;;CHEEMA AMRITA K,GEORGETOWN UNIVERSITY (2019-08-29);;UNIVERSITY OF ROCHESTER (2019-08-12),https://lens.org/036-881-490-811-032,Granted Patent,yes,1,0,3,3,0,A61P25/28;;G01N33/5308;;G01N33/6896;;G01N2800/2814;;G01N2800/50;;G01N2800/52;;G01N33/6896;;G01N2560/00;;G01N2800/2814;;G01N2800/50;;G01N2800/52,G01N33/68,,5,4,000-456-556-730-283;;092-007-236-091-818;;049-393-259-293-948;;021-426-045-667-387,pmc5985530;;10.1016/j.neurobiolaging.2016.11.007;;27939698;;10.1038/nm.3466;;pmc5360460;;24608097;;19079617;;pmc2600464;;pmc5471778;;10.1159/000466688;;28626469,"Mapstone, M. et al.) What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer's disease. Neurobiology of Aging. Mar. 2017, Epub Nov. 21, 2016, vol. 51; pp. 148-155.;;Mapstone, M. et al.) Plasma phospholipids identity antecedent memory impairment in older adults. Nature Medicine. Apr. 2014, Epub Mar. 9, 2014, vol. 20, No. 4; pp. 415-418.;;Yi, J. et al.) L-Arginine and Alzheimer's Disease. International Journal of Clinical & Experimental Pathology. 2009, Epub Oct. 2, 2008, vol. 2, No. 3; pp. 211-238.;;Corso, G. et al.) Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia. Dementia and Geriatric Cognitive Disorders Extra. May 4, 2017, vol. 7, No. 1; pp. 143-159.;;International Search Report and Written Opinion dated Apr. 20, 2018 in corresponding International Application No. PCT/US2018/016590.",ACTIVE
41,US,A1,US 2017/0052204 A1,151-377-350-053-977,2017-02-23,2017,US 201515307988 A,2015-04-30,US 201515307988 A;;US 201461986555 P;;US 2015/0028550 W,2014-04-30,Metabolic and Genetic Biomarkers for Memory Loss,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and also analyzing the gene expression profile from leukocytes and comparing the value of the subject's biomarker profile (lipidomic profile plus gene expression profile) with the value of a normal biomarker profile. A change in the value of the subject's biomarker profile, including a change in the subject's biomarker profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;MAPSTONE MARK E;;CHEEMA AMRITA K;;FIANDACA MASSIMO S,GEORGETOWN UNIVERSITY (2015-05-21);;UNIVERSITY OF ROCHESTER (2015-07-01),https://lens.org/151-377-350-053-977,Patent Application,yes,0,4,4,4,0,C12Q1/6883;;C12Q1/6883;;C12Q2600/158;;C12Q2600/158;;G01N33/92;;G01N33/92;;G01N2570/00;;G01N2570/00;;G01N2800/2814;;G01N2800/2814;;G01N2800/52;;G01N2800/52,G01N33/92;;C12Q1/68,,0,0,,,,DISCONTINUED
42,WO,A2,WO 2023/183594 A2,169-850-953-750-063,2023-09-28,2023,US 2023/0016270 W,2023-03-24,US 202263323830 P;;US 202263326236 P;;US 202263341841 P;;US 202263393196 P;;US 202363438164 P,2022-03-25,METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE,"Aspects of the disclosure relate to compositions and methods useful for treating Parkinson's disease. In some embodiments, the disclosure provides a method for treating Parkinson's disease comprising administration of a viral vector comprising a GDNF nucleic acid sequence. In some embodiments, administration is locally to the subject putamen. In some embodiments, administration is systemically, e.g., via the viral vector comprising a modified viral capsid, such as for preferentially targeting cells in the CNS or PNS.",ASKLEPIOS BIOPHARMACEUTICAL INC,BANKIEWICZ KRYSTOF S;;KELLS ADRIAN P;;VAN LAAR AMBER;;FIANDACA MASSIMO S,,https://lens.org/169-850-953-750-063,Patent Application,yes,0,0,2,2,64,C12N15/86;;C12N2750/14143;;A61K48/005;;A61K48/0075;;C07K14/4705,C12N15/86;;A61K48/00,,0,0,,,,PENDING
43,EP,B1,EP 3060305 B1,160-228-684-282-697,2019-04-03,2019,EP 14855189 A,2014-10-21,US 201361893762 P;;US 2014/0061578 W,2013-10-21,BIOMARKERS FOR MEMORY LOSS,,UNIV GEORGETOWN,FEDEROFF HOWARD J;;MAPSTONE MARK E;;CHEEMA AMRITA K;;FIANDACA MASSIMO S,,https://lens.org/160-228-684-282-697,Granted Patent,yes,4,0,8,8,0,G01N2570/00;;G01N2800/2814;;G01N33/92;;A61P25/28;;G01N2570/00;;G01N2800/2814;;G01N33/92;;G01N2405/00;;G01N2405/04;;G01N2800/2821;;G01N2800/52,A61P25/28,,5,0,,,"XIANLIN HAN ET AL: ""Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics"", PLOS ONE, vol. 6, no. 7, 1 July 2011 (2011-07-01), page e21643, XP055351379, DOI: 10.1371/journal.pone.0021643;;MARK MAPSTONE ET AL: ""Plasma phospholipids identify antecedent memory impairment in older adults"", NATURE MEDICINE, vol. 20, no. 4, 1 January 2014 (2014-01-01), pages 415-418, XP055351904, ISSN: 1078-8956, DOI: 10.1038/nm.3466;;CHAN ET AL.: 'Comparative lipidomic analysis of mouse and human brain with Alzheimer disease' J BIOL CHEM. vol. 287, 01 December 2011, pages 2678 - 2688, XP055339718;;ASTARITA ET AL.: 'Towards a whole-body systems [multi-organ) lipidomics in Alzheimer's disease' PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS. vol. 85, 04 May 2011, pages 197 - 203, XP028309053;;HAN ET AL.: 'Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease' BIOCHIM BIOPHYS ACTA vol. 1801, 01 February 2010, pages 774 - 783, XP027086263",ACTIVE
44,US,A1,US 2017/0192018 A1,020-703-502-353-030,2017-07-06,2017,US 201515313163 A,2015-05-27,US 201515313163 A;;US 201462003367 P;;US 2015/0032623 W,2014-05-27,METABOLIC BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;FEDEROFF HOWARD J;;ZHONG XIAOGANG;;CHEEMA AMRITA K,GEORGETOWN UNIVERSITY (2015-06-15);;UNIVERSITY OF ROCHESTER (2015-07-01),https://lens.org/020-703-502-353-030,Patent Application,yes,0,0,6,6,0,G01N33/6896;;G01N33/6896;;G01N33/92;;G01N33/92;;G01N2570/00;;G01N2570/00;;G01N2800/28;;G01N2800/28,G01N33/68;;G01N33/92,,3,3,010-211-322-795-751;;023-137-451-973-365;;048-824-594-633-263,15465626;;10.1016/j.neurobiolaging.2004.02.016;;9482271;;10.1023/a:1022457605436;;19720082;;10.1016/j.plipres.2009.08.004,"Walter et al., Neurobiol. of Ageing, 2004, 25:1299-1303;;Prasad et al. Neurochem. Res., 1998, 23(1):81-8;;Jones et al., Progress in Lipid Res., 2010, 49:61-75",ACTIVE
45,WO,A1,WO 2017/066739 A1,001-474-806-935-78X,2017-04-20,2017,US 2016/0057295 W,2016-10-17,US 201562242461 P,2015-10-16,PROTEIN BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's proteomic profile and comparing the value of the subject's proteomic profile with the value of a normal proteomic profile. A change in the value of the subject's proteomic profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;FIANDACA MASSIMO S;;CHEEMA AMRITA K;;MAPSTONE MARK E;;ZHONG XIAOGANG,,https://lens.org/001-474-806-935-78X,Patent Application,yes,4,2,3,3,0,G16B20/00;;Y02A90/10;;G16B20/00;;G16H50/30;;G16H50/20;;G01N33/6896;;G01N2570/00;;G01N2800/2814;;G01N2800/60,G16B20/00;;G16B45/00,,1,1,061-260-074-654-837,10.1074/mcp.m500207-mcp200;;16199891,"HU ET AL.: ""Comparative proteomic analysis of intra-and interindividual variation in human cerebrospinal fluid"", MOLECULAR & CELLULAR PROTEOMICS, vol. 4, no. 12, 2005, pages 2000 - 2009, XP055374832",PENDING
46,EP,A2,EP 3930711 A2,117-290-940-414-774,2022-01-05,2022,EP 20753139 A,2020-02-05,US 201962801271 P;;US 2020/0016820 W,2019-02-05,MATERIALS AND METHODS FOR TREATING A NEURODEGENERATIVE DISEASE,,UNIV CALIFORNIA;;UNIV GEORGETOWN,FEDEROFF HOWARD J;;SUBRAMANIAM SUDHAKAR RAJA;;FIANDACA MASSIMO S;;MAPSTONE MARK E;;SU XIAOMIN,,https://lens.org/117-290-940-414-774,Patent Application,yes,0,0,11,11,0,A61K31/216;;A61K31/352;;A61P25/28;;A61K45/06;;A61K36/82;;A61K36/185;;A61P25/28;;A61K31/13;;A61K31/216;;A61K31/27;;A61K31/352;;A61K31/428;;A61K31/4745;;A61K36/185;;A61K36/82,A61K31/4164;;A61K31/496;;A61K45/06,,0,0,,,,PENDING
47,US,A1,US 2022/0401404 A1,003-991-146-892-558,2022-12-22,2022,US 202017428867 A,2020-02-05,US 202017428867 A;;US 201962801271 P;;US 2020/0016820 W,2019-02-05,Co-Administration Therapy to Prevent Neurodegeneration and Enhance Neuroprotection,Described herein are materials and methods for the treatment of neurodegenerative diseases by administering a combination of fenofibrate and kaempferol.,UNIV CALIFORNIA;;UNIV GEORGETOWN,FEDEROFF HOWARD J;;SUBRAMANIAM SUDHAKAR RAJA;;FIANDACA MASSIMO S;;MAPSTONE MARK E;;SU XIAOMIN,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2020-08-23);;GEORGETOWN UNIVERSITY (2021-11-04),https://lens.org/003-991-146-892-558,Patent Application,yes,0,0,11,11,0,A61K31/216;;A61K31/352;;A61P25/28;;A61K45/06;;A61K36/82;;A61K36/185;;A61P25/28;;A61K31/13;;A61K31/216;;A61K31/27;;A61K31/352;;A61K31/428;;A61K31/4745;;A61K36/185;;A61K36/82,A61K31/352;;A61K31/13;;A61K31/216;;A61K31/27;;A61K31/428;;A61K31/4745;;A61K36/185;;A61K36/82;;A61P25/28,,0,0,,,,PENDING
48,EP,A4,EP 3149473 A4,118-038-553-728-732,2018-03-14,2018,EP 15800012 A,2015-05-27,US 201462003367 P;;US 2015/0032623 W,2014-05-27,METABOLIC BIOMARKERS FOR MEMORY LOSS,,UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;FEDEROFF HOWARD J;;ZHONG XIAOGANG;;CHEEMA AMRITA K,,https://lens.org/118-038-553-728-732,Search Report,no,1,0,6,6,0,G01N2570/00;;G01N2800/28;;G01N33/92;;G01N33/6896;;G01N2570/00;;G01N2800/28;;G01N33/92;;G01N33/6896,G01N33/68;;G01N33/92,,3,2,046-579-746-715-155;;004-387-952-367-614,16895547;;10.1111/j.1440-1681.2006.04425.x;;26617567;;pmc4642213;;10.3389/fneur.2015.00237,"AL-MAJED A A ET AL: ""Carnitine esters prevent oxidative stress damage and energy depletion following transient forebrain ischaemia in the rat hippocampus"", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, WILEY-BLACKWELL PUBLISHING ASIA, AU, vol. 33, no. 8, 1 August 2006 (2006-08-01), pages 725 - 733, XP002649676, ISSN: 0305-1870;;MASSIMO S. FIANDACA ET AL: ""Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer's Disease"", FRONTIERS IN NEUROLOGY, vol. 6, 12 November 2015 (2015-11-12), XP055418247, ISSN: 1664-2295, DOI: 10.3389/fneur.2015.00237;;See also references of WO 2015183917A2",PENDING
49,WO,A2,WO 2015/183917 A2,089-716-833-580-779,2015-12-03,2015,US 2015/0032623 W,2015-05-27,US 201462003367 P,2014-05-27,METABOLIC BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;FEDEROFF HOWARD J;;ZHONG XIAOGANG;;CHEEMA AMRITA K,,https://lens.org/089-716-833-580-779,Patent Application,yes,0,3,6,6,0,G01N2570/00;;G01N2800/28;;G01N33/92;;G01N33/6896;;G01N2570/00;;G01N2800/28;;G01N33/92;;G01N33/6896,G01N33/48,,1,0,,,"NATURE MEDICINE, no. 20, 2014, pages 415 - 418",PENDING
50,WO,A3,WO 2015/183917 A3,059-166-446-359-589,2016-03-17,2016,US 2015/0032623 W,2015-05-27,US 201462003367 P,2014-05-27,METABOLIC BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;FEDEROFF HOWARD J;;ZHONG XIAOGANG;;CHEEMA AMRITA K,,https://lens.org/059-166-446-359-589,Search Report,yes,3,0,6,6,0,G01N33/6896;;G01N33/6896;;G01N33/92;;G01N33/92;;G01N2570/00;;G01N2570/00;;G01N2800/28;;G01N2800/28,G01N33/50,,2,1,092-007-236-091-818,10.1038/nm.3466;;pmc5360460;;24608097,"MAPSTONE ET AL.: ""Plasma phospholipids identify antecedent memory impairment in older adults"", NAT MED., vol. 20, 9 March 2014 (2014-03-09), pages 415 - 418, XP055351904;;See also references of EP 3149473A4",PENDING
51,US,B2,US 10900977 B2,156-390-469-011-342,2021-01-26,2021,US 201615768798 A,2016-10-17,US 201615768798 A;;US 201562242461 P;;US 2016/0057295 W,2015-10-16,Protein biomarkers for memory loss,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's proteomic profile and comparing the value of the subject's proteomic profile with the value of a normal proteomic profile. A change in the value of the subject's proteomic profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;FIANDACA MASSIMO S;;CHEEMA AMRITA K;;MAPSTONE MARK E;;ZHONG XIAOGANG,GEORGETOWN UNIVERSITY (2015-11-01);;UNIVERSITY OF ROCHESTER (2015-10-28),https://lens.org/156-390-469-011-342,Granted Patent,yes,4,0,3,3,0,G16B20/00;;Y02A90/10;;G16B20/00;;G16H50/30;;G16H50/20;;G01N33/6896;;G01N2570/00;;G01N2800/2814;;G01N2800/60,A61K38/00;;C12Q1/68;;G01N33/567;;G01N33/68;;G16B20/00;;G16B45/00;;G16H50/20;;G16H50/30,,2,1,061-260-074-654-837,10.1074/mcp.m500207-mcp200;;16199891,"Hu et al., “Comparative Proteomic Analysis of Intra- and Interindividual Variation in Human Cerebrospinal Fluid,” Molecular & Cellular Proteomics, vol. 4, No. 12, pp. 2000-2009 (2005).;;International Search Report and Written Opinion issued in corresponding International Application No. PCT/US2016/057295 dated Jan. 11, 2017.",ACTIVE
52,AU,A1,AU 2020/219140 A1,126-340-726-264-25X,2022-03-24,2022,AU 2020/219140 A,2020-02-05,US 201962801271 P;;US 2020/0016820 W,2019-02-05,Materials and methods for treating a neurodegenerative disease,Described herein are materials and methods for the treatment of neurodegenerative diseases by administering a combination of fenofibrate and kaempferol.,UNIV GEORGETOWN;;UNIV CALIFORNIA,FEDEROFF HOWARD J;;SUBRAMANIAM SUDHAKAR RAJA;;FIANDACA MASSIMO S;;MAPSTONE MARK E;;SU XIAOMIN,,https://lens.org/126-340-726-264-25X,Patent Application,no,0,0,11,11,0,A61K31/216;;A61K31/352;;A61P25/28;;A61K45/06;;A61K36/82;;A61K36/185;;A61P25/28;;A61K31/13;;A61K31/216;;A61K31/27;;A61K31/352;;A61K31/428;;A61K31/4745;;A61K36/185;;A61K36/82,A61K31/4164;;A61K31/496;;A61K45/06,,0,0,,,,PENDING
53,EP,A4,EP 3930711 A4,176-234-118-821-854,2023-01-11,2023,EP 20753139 A,2020-02-05,US 201962801271 P;;US 2020/0016820 W,2019-02-05,MATERIALS AND METHODS FOR TREATING A NEURODEGENERATIVE DISEASE,,UNIV CALIFORNIA;;UNIV GEORGETOWN,FEDEROFF HOWARD J;;SUBRAMANIAM SUDHAKAR RAJA;;FIANDACA MASSIMO S;;MAPSTONE MARK E;;SU XIAOMIN,,https://lens.org/176-234-118-821-854,Search Report,no,0,0,11,11,0,A61K31/216;;A61K31/352;;A61P25/28;;A61K45/06;;A61K36/82;;A61K36/185;;A61P25/28;;A61K31/13;;A61K31/216;;A61K31/27;;A61K31/352;;A61K31/428;;A61K31/4745;;A61K36/185;;A61K36/82,A61K31/216;;A61K31/352;;A61K36/185;;A61K36/82;;A61K45/06;;A61P25/28,,2,2,075-795-364-373-290;;064-049-184-381-791,10.1111/j.1476-5381.2011.01389.x;;pmc3195922;;21449918;;10.1248/bpb.34.1291;;21804220,"SE PARK ET AL: ""Kaempferol acts through mitogen-activated protein kinases and protein kinase B/AKT to elicit protection in a model of neuroinflammation in BV2 microglial cells"", BRITISH JOURNAL OF PHARMACOLOGY, WILEY-BLACKWELL, UK, vol. 164, no. 3, 8 September 2011 (2011-09-08), pages 1008 - 1025, XP071170976, ISSN: 0007-1188, DOI: 10.1111/J.1476-5381.2011.01389.X;;LI SHEN ET AL: ""Neuroprotective Effect of Kaempferol against a 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Mouse Model of Parkinson's Disease"", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 34, no. 8, 1 January 2011 (2011-01-01), JP, pages 1291 - 1296, XP093003616, ISSN: 0918-6158, DOI: 10.1248/bpb.34.1291",PENDING
54,US,A1,US 2018/0306811 A1,188-900-445-916-508,2018-10-25,2018,US 201615768798 A,2016-10-17,US 201615768798 A;;US 201562242461 P;;US 2016/0057295 W,2015-10-16,PROTEIN BIOMARKERS FOR MEMORY LOSS,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's proteomic profile and comparing the value of the subject's proteomic profile with the value of a normal proteomic profile. A change in the value of the subject's proteomic profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FEDEROFF HOWARD J;;FIANDACA MASSIMO S;;CHEEMA AMRITA K;;MAPSTONE MARK E;;ZHONG XIAOGANG,GEORGETOWN UNIVERSITY (2015-11-01);;UNIVERSITY OF ROCHESTER (2015-10-28),https://lens.org/188-900-445-916-508,Patent Application,yes,0,0,3,3,0,G16B20/00;;Y02A90/10;;G16B20/00;;G16H50/30;;G16H50/20;;G01N33/6896;;G01N2570/00;;G01N2800/2814;;G01N2800/60,G01N33/68;;G16B20/00;;G16B45/00;;G16H50/20;;G16H50/30,,0,0,,,,ACTIVE
55,US,B2,US 10890589 B2,087-151-873-680-872,2021-01-12,2021,US 201515313163 A,2015-05-27,US 201515313163 A;;US 201462003367 P;;US 2015/0032623 W,2014-05-27,Metabolic biomarkers for memory loss,"The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.",UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;FEDEROFF HOWARD J;;ZHONG XIAOGANG;;CHEEMA AMRITA K,GEORGETOWN UNIVERSITY (2015-06-15);;UNIVERSITY OF ROCHESTER (2015-07-01),https://lens.org/087-151-873-680-872,Granted Patent,yes,4,0,6,6,0,G01N33/6896;;G01N33/6896;;G01N33/92;;G01N33/92;;G01N2570/00;;G01N2570/00;;G01N2800/28;;G01N2800/28,A61K38/00;;C12Q1/68;;G01N33/567;;G01N33/68;;G01N33/92,,8,6,048-824-594-633-263;;023-137-451-973-365;;010-211-322-795-751;;092-007-236-091-818;;129-720-913-500-151;;004-387-952-367-614,19720082;;10.1016/j.plipres.2009.08.004;;9482271;;10.1023/a:1022457605436;;15465626;;10.1016/j.neurobiolaging.2004.02.016;;10.1038/nm.3466;;pmc5360460;;24608097;;18855770;;10.2144/000112834;;pmc2575809;;26617567;;pmc4642213;;10.3389/fneur.2015.00237,"Jones et al., Progress in Lipid Res., 2010, 49:61-75.;;Prasad et al. Neurochem. Res., 1998, 23(1):81-8.;;Walter et al., Neurobiol. of Ageing, 2004, 25:1299-1303.;;International Search Report issued in the corresponding International Application No. PCT/US2015/032623 dated Sep. 1, 2015.;;Mapstone et al., “Plasma phospholipids identify antecedent memory impairment in older adults,” Nature Medicine 20:415-418 (2014).;;CRAIG BELON ET AL: ""Monitoring helicase activity with molecular beacons"", BIOTECHNIQUES, vol. 45, no. 4, 1 October 2008 (2008-10-01), pages 433 - 442, XP002649476;;MASSIMO S. FIANDACA, XIAOGANG ZHONG, AMRITA K. CHEEMA, MICHAEL H. ORQUIZA, SWATHI CHIDAMBARAM, MING T. TAN, CAROLE ROAN GRESENZ, K: ""Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer’s Disease"", FRONTIERS IN NEUROLOGY, FRONTIERS RESEARCH FOUNDATION, vol. 6, 12 November 2015 (2015-11-12), XP055418247, ISSN: 1664-2295, DOI: 10.3389/fneur.2015.00237;;Supplementary European Search Report issued in corresponding European Application No. 15800012.5 dated Feb. 12, 2018.",ACTIVE
56,CA,A1,CA 3129050 A1,171-493-011-994-186,2020-08-13,2020,CA 3129050 A,2020-02-05,US 201962801271 P;;US 2020/0016820 W,2019-02-05,MATERIALS AND METHODS FOR TREATING A NEURODEGENERATIVE DISEASE,Described herein are materials and methods for the treatment of neurodegenerative diseases by administering a combination of fenofibrate and kaempferol.,UNIV CALIFORNIA,SUBRAMANIAM SUDHAKAR RAJA;;FEDEROFF HOWARD J;;FIANDACA MASSIMO S;;MAPSTONE MARK E;;SU XIAOMIN,,https://lens.org/171-493-011-994-186,Patent Application,no,0,0,11,11,0,A61K31/216;;A61K31/352;;A61P25/28;;A61K45/06;;A61K36/82;;A61K36/185;;A61P25/28;;A61K31/13;;A61K31/216;;A61K31/27;;A61K31/352;;A61K31/428;;A61K31/4745;;A61K36/185;;A61K36/82,A61K31/353;;A61K31/496;;A61K45/06,,0,0,,,,PENDING
57,MX,A,MX 2021009413 A,000-431-852-510-161,2022-01-18,2022,MX 2021009413 A,2020-02-05,US 201962801271 P;;US 2020/0016820 W,2019-02-05,MATERIALS AND METHODS FOR TREATING A NEURODEGENERATIVE DISEASE.,Described herein are materials and methods for the treatment of neurodegenerative diseases by administering a combination of fenofibrate and kaempferol.,UNIV CALIFORNIA,FEDEROFF HOWARD J;;SUBRAMANIAM SUDHAKAR RAJA;;FIANDACA MASSIMO S;;MAPSTONE MARK E;;SU XIAOMIN,,https://lens.org/000-431-852-510-161,Patent Application,no,0,0,11,11,0,A61K31/216;;A61K31/352;;A61P25/28;;A61K45/06;;A61K36/82;;A61K36/185;;A61P25/28;;A61K31/13;;A61K31/216;;A61K31/27;;A61K31/352;;A61K31/428;;A61K31/4745;;A61K36/185;;A61K36/82,A61K31/4164;;A61K31/496;;A61K45/06,,0,0,,,,PENDING
58,EP,A2,EP 3149473 A2,030-552-326-022-52X,2017-04-05,2017,EP 15800012 A,2015-05-27,US 201462003367 P;;US 2015/0032623 W,2014-05-27,METABOLIC BIOMARKERS FOR MEMORY LOSS,,UNIV GEORGETOWN;;UNIV ROCHESTER,FIANDACA MASSIMO S;;MAPSTONE MARK E;;FEDEROFF HOWARD J;;ZHONG XIAOGANG;;CHEEMA AMRITA K,,https://lens.org/030-552-326-022-52X,Patent Application,yes,0,0,6,6,0,G01N33/6896;;G01N33/6896;;G01N33/92;;G01N33/92;;G01N2570/00;;G01N2570/00;;G01N2800/28;;G01N2800/28,G01N33/50,,0,0,,,,PENDING
59,US,A1,US 2020/0239959 A1,134-301-007-891-685,2020-07-30,2020,US 202016751700 A,2020-01-24,US 202016751700 A;;US 201962796568 P,2019-01-24,Plasma MicroRNA Markers of Upper Limb Recovery Following Human Stroke,"Methods of determining if a subject has an increased risk of poor recovery after suffering a stroke and methods of treating a subject recovering from a stroke. The methods comprise analyzing at least one plasma sample taken from the subject to assess a microRNA (miRNA) profile of the subject and comparing the subject's miRNA profile with a normal miRNA profile, to determine if the subject's miRNA profile is altered compared to a normal miRNA profile. An alteration of the subject's miRNA profile is indicative that the subject has an increased risk of poor recovery after suffering a stroke.",UNIV GEORGETOWN,EDWARDSON MATTHEW A;;ZHONG XIAOGANG;;FIANDACA MASSIMO S;;FEDEROFF HOWARD J;;CHEEMA AMRITA K;;DROMERICK ALEXANDER W,,https://lens.org/134-301-007-891-685,Patent Application,yes,0,0,1,1,0,C12Q1/6883;;C12Q1/6883;;C12Q2600/178;;C12Q2600/178;;G01N2800/50;;G01N2800/54,C12Q1/6883,,0,0,,,,DISCONTINUED
